CASE PRESENTATION {#s1}
=================

This right-handed girl had onset of seizures at 2 years of age. Brain magnetic resonance imaging (MRI) was initially normal but was repeated at age 10 because of progressive headache and revealed a left temporal tip abnormality suggestive of ganglioglioma. She underwent resection of the lesion, which was reported as pleomorphic xanthoastrocytoma (PXA) with anaplastic features. Immunohistochemical (IHC) stain for BRAF V600E was negative. She remained seizure-free, but had local recurrence on MRI 6 months later, prompting re-resection. Pathology was identical, and IHC for BRAF V600E was again negative. She was referred for involved field radiation therapy, but following treatment had persistent tumor on MRI, with new contralateral disease, which was treated by stereotactic irradiation. Follow-up MRI showed further disease progression, and chemotherapy was initiated with temozolomide. Subsequent MRIs have shown stable disease in response to temozolomide.

METHODS {#s2}
=======

Whole-exome and transcriptome sequencing was performed on DNA and RNA from blood and tumor (second surgery). Exome sequences were captured using Agilent SureSelect reagent V5+UTRs and sequenced on the Illumina HiSeq2500. An average coverage of 214- and 181-fold was obtained in the normal and tumor samples, respectively. Potential variants were filtered by known pathogenicity (ClinVar, Human Gene Mutation Database \[HGMD\], Online Mendelian Inheritance in Man \[OMIM\], Catalogue of Somatic Mutations in Cancer \[COSMIC\]) and frequency in the general population (The 1000 Genomes Project, Exome Variant Server, and our internal database). Copy-number changes were defined using EXCAVATOR software ([@HSIAOMCS001396C5]). Transcriptome sequencing was performed on RNA isolated from tumor. Transcriptome alignment was performed using the Tuxedo suite software package ([@HSIAOMCS001396C8]). One hundred and forty-eight million uniquely mapped reads were obtained. Translocations were detected using the FusionMap software. In view of BRAF V600E negativity, tumor was subjected to further IHC staining on formalin-fixed paraffin-embedded (FFPE) sections using standard procedures and the following antibodies: IgG control (sc-2027, Santa Cruz Biotechnology, Inc.), phospho-ERK1/2 (4370, Cell Signaling Technology), and phospho-MEK1/2 (2338, Cell Signaling Technology).

Genomic Analysis {#s2a}
----------------

A total of 124 somatic variants were identified and evaluated for pathogenicity and clinical significance. None were found to be clinically significant. Somatic copy-number changes identified included gain of Chromosome 7 (1--159,138,663), loss of Chromosome 13 (1--115,169,878), and copy-number neutral loss of heterozygosity of 9p (1--47,432,582) with copy-number loss of 9p21.3 (20,902,560--23,776,437, which includes the *CDKN2A* gene). Of note, transcriptome sequencing detected a novel *TMEM106B*-*BRAF* fusion on Chromosome 7, involving exons 1--3 of *TMEM106B* fused to exons 8--18 of *BRAF* ([Fig. 1](#HSIAOMCS001396F1){ref-type="fig"}A; [Table 1](#HSIAOMCS001396TB1){ref-type="table"}).

![TMEM106B-BRAF activates MEK-ERK pathway. (*A*) Transcriptional readout of the *TMEM106B* and *BRAF* loci from RNA-seq performed on primary tumor material. The site of translocation in each locus is indicated (red arrow). (*B*) Junctional sequence and reading frame. (*C*) Immunocytochemistry analysis of MEK/ERK pathway activity in patient\'s tumor utilizing phosphorylation-specific antibodies for phospho-MEK1/2 and phospho-ERK1/2. Scale bars, 100 µm.](HsiaoMCS001396_F1){#HSIAOMCS001396F1}

###### 

*TMEM106B-BRAF* fusion found in patient

  Gene1        Gene2    Position 1        Position 2         Transcript 1                        Exon number 1   Transcript strand 1  Transcript 2      Exon number 2   Transcript strand 2  Fusion junction sequence                                          Frameshift class
  ------------ -------- ----------------- ------------------ ---------------------------------- --------------- --------------------- ---------------- --------------- --------------------- ---------------------------------------------------------------- ------------------
  *TMEM106B*   *BRAF*   Chr 7: 12258147   Chr 7: 140494267   NM_001134232_Chr7;NM_018374_Chr7         3;4                \+           NM_004333_Chr7          8                 \-           `TAGTGATCAGAGATTAAGGCCAAGAAGAACgccccaaattctcaccagtccgtctccttc`        In-frame

Clinical Interpretation {#s2b}
-----------------------

The primary treatment of PXA is surgical resection, and the outcome is generally favorable. Pathology is notable for anaplasia in ∼15% of PXAs, but there is no consensus regarding any advantage of adjuvant postsurgical therapy ([@HSIAOMCS001396C6]). *BRAF* V600E mutation is found in nearly 70% of PXAs ([@HSIAOMCS001396C3]). Activation of BRAF by chromosomal rearrangement, such as the *KIAA1549-BRAF* fusion, which is common in pilocytic astrocytomas, is rare in PXA ([@HSIAOMCS001396C1]). BRAF is a serine/threonine kinase downstream from RAS in the mitogen-activated protein kinase (MAPK) signaling pathway. Mutation in *BRAF* constitutively activates the RAS/RAF/MEK/ERK signaling pathway. The possibility of targeted therapy for BRAF V600E mutated PXA has now been realized, with the report of transient single-agent activity of the selective BRAF V600E inhibitor vemurafenib ([@HSIAOMCS001396C2]). TMEM106B functions in dendrite morphogenesis and maintenance by regulating lysosomal trafficking and may be associated with frontotemporal dementia. The *TMEM106B-BRAF* fusion in our case results in replacement of the amino-terminal regulatory domain of BRAF with the amino-terminal region of TMEMB106B while leaving the kinase domain of BRAF intact ([Fig. 1](#HSIAOMCS001396F1){ref-type="fig"}B). Although not previously reported, this fusion is predicted to result in activation of BRAF signaling, based on the activity of similar BRAF fusion proteins. We used activation-state-specific immunohistochemical staining for phospho-ERK1/2 and phospho-MEK to demonstrate activation of the MEK--ERK pathway downstream from BRAF signaling ([Fig. 1](#HSIAOMCS001396F1){ref-type="fig"}C). Given reports showing that tumors harboring the KIAA1549-BRAF fusion are not sensitive to vemurafenib and lead to paradoxical MEK--ERK activation, we expect PXA harboring *TMEM106B-BRAF* fusion will not be sensitive to vemurafenib as well, but could be sensitive to MEK inhibitors or second-generation RAF inhibitors such as PLX8394 ([@HSIAOMCS001396C7]; [@HSIAOMCS001396C4]; [@HSIAOMCS001396C9]).

ADDITIONAL INFORMATION {#s3}
======================

Data Deposition and Access {#s3a}
--------------------------

The data set supporting this article can be obtained from the cBioPortal for Cancer Genomics (<http://cbioportal.org>). The data set supporting the conclusions of this article can be obtained from the cBioPortal for Cancer Genomics (http://cbioportal.org) by selecting the DATA SETS tab and clicking on the citation listed in the Reference column. The variant has been deposited in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) under accession number SCV000328979.
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